A case of toxic epidermal necrolysis caused by sorafenib and sintilimab

VernacularTitle:索拉非尼联合信迪利单抗致中毒性表皮坏死松解症1例
Author: Lin DENG ¹ ; Chao REN ; Tao SUN ; Xi LI ; Shun GUO ; Ang ZHOU
Author Information

1. 空军军医大学第二附属医院肿瘤科(西安 710038)
Keywords: Sorafenib; Sintilimab; Toxic epidermal necrolysis; Adverse drug reactions
From:Chinese Journal of Pharmacoepidemiology 2024;33(2):224-229
CountryChina
Language:Chinese
Abstract: A 67-year-old female patient with postoperative recurrence of stage Ⅳright renal cell carcinoma and multiple intracranial metastases was treated with sorafenib and sintilimab.Within 2 weeks,the patient had a fever and red spotted rash in facial,back,buttocks and limb.After 2 days,the fever completely relieved,but subcutaneous exudation appeared on the skin of both elbow joints,buttocks,and outer thighs,followed by gradual epidermal lysis and detachment with skin ulceration.After 4 days,the patient's epidermolysis area was greater than 30％of the body surface area.The patient was diagnosed with toxic epidermal necrolysis(TEN).The adverse reaction correlation was assessed by ALDEN SCORE sheet.The adverse reaction of TEN was"likely"caused by sorafenib and sintilimab.After withdrawal and treatment,the TEN was cured.This paper explores the correlation between the TEN and the combination use of sorafenib and sintilimab and the management.This paper will provide reference for the early diagnosis and correct treatment of TEN.